Trials / Unknown
UnknownNCT01341132
Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (estimated)
- Sponsor
- San Francisco Veterans Affairs Medical Center · Federal
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector computed tomography (CT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | MRI Scan of the Liver enhanced with Eovist | 10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-06-01
- First posted
- 2011-04-25
- Last updated
- 2011-04-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01341132. Inclusion in this directory is not an endorsement.